J&J Settles Pennsylvania Risperdal Breast Growth Case

PHILADELPHIA — Johnson & Johnson Co. (NYSE: JNJ) and its subsidiary have settled a Risperdal injury case on the first day of trial, resolving claims that they failed to adequately warn of risks associated with the antipsychotic drug, including the growth of breast tissue in male patients.

The case, filed against J&J and Janssen Pharmaceuticals Inc. in the Philadelphia County Court of Common Pleas, was confidentially settled on Sept. 10. Judge George W. Overton presided.

According to the Feb. 2011 second amended complaint, Banks, 21, was prescribed Risperdal in 2000 when he was 9 years old and took the drug …